Neurological Disorder Drugs Market Report 2026

Neurological Disorder Drugs Market Overview

• Neurological Disorder Drugs market size has reached to $89.24 billion in 2025 • Expected to grow to $116.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Rising Neurological Disorders Drive Growth In Drugs Market • Market Trend: Advancements In Ocrelizumab Drug Delivery Technologies Enhance Treatment Accessibility And Clinical Outcomes In Multiple Sclerosis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurological Disorder Drugs Market?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected. The main types of drug classes in neurological disorders are cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are medications that prevent the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. Which can be used for various indications such as epilepsy, alzheimer’s disease, parkinson’s disease, multiple sclerosis, cerebrovascular disease, and others, through various routes of administration, including oral, parenteral, and others. And these can be distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and end users are hospitals, specialty clinics, home care, and others.

What Is The Neurological Disorder Drugs Market Growth Forecast?

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $116.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to advancements in neurological drug development pipelines, growing burden of alzheimer’s and parkinson’s disease, increasing access to neurological care in emerging markets, rising demand for personalized neurology treatments, expansion of homecare and outpatient neurological therapy. Major trends in the forecast period include growing adoption of disease-modifying neurological therapies, rising focus on early diagnosis and long-term disease management, increased demand for combination drug therapies, expansion of oral and home-based neurological treatments, higher emphasis on symptom management and quality of life improvement.

Global Neurological Disorder Drugs Market Segmentation

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes 2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegments: 1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine 2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists 3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics 4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic 5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Is The Driver Of The Neurological Disorder Drugs Market?

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological disorder drugs market going forward. Neurological disorders refer to the conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities, leading to various symptoms. The increase in neurological diseases is attributed to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs play a critical role in managing these complex conditions, offering relief from symptoms, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs industry.

Key Players In The Global Neurological Disorder Drugs Market

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Global Neurological Disorder Drugs Market Trends and Insights

Major companies operating in the neurological disorder drugs market are focusing on developing innovative solutions such as Ocrelizumab-based therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, helping reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly, approximately 10-minute subcutaneous injection, marking the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is designed to improve convenience, expand access to therapy, and support clinical workflow efficiency by offering a faster, non-intravenous method of administration.

What Are Latest Mergers And Acquisitions In The Neurological Disorder Drugs Market?

In March 2024, Bristol-Myers Squibb Company (BMS), a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. Through this acquisition, BMS aims to strengthen its global neuroscience portfolio by gaining Karuna’s lead asset KarXT (xanomeline–trospium), a first-in-class muscarinic receptor modulator in development for neurological and psychiatric indications such as schizophrenia and Alzheimer’s disease–related psychosis. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company specializing in novel therapies for neurological and neuropsychiatric conditions.

Regional Insights

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurological Disorder Drugs Market?

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurological Disorder Drugs Market Report 2026?

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.